Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study
A promising cancer drug combination proved too toxic to pursue further, illustrating how mechanistic promise doesn't always translate to safe clinical use.
This phase 1b trial evaluating garsorasib (KRAS G12C inhibitor) combined with pembrolizumab and platinum doublet chemotherapy in first-line NSCLC showed antitumor activity (ORR 59%) but encountered a prohibitive safety profile with grade 3+ adverse events in 94% of patients. The study did not proceed to phase 2, suggesting this triple-combination regimen exceeds tolerable toxicity boundaries despite mechanistic rationale.
What the study was
- Study design
- Phase 1b clinical trial
- Category
- T6: Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- Maturity
- Validated
- Journal
- JTO Clinical and Research Reports
Why it surfaced
Negative clinical trial with important pipeline intelligence: garsorasib triple combination is too toxic for phase 2 progression in KRAS G12C NSCLC, narrowing the therapeutic window and redirecting combination strategy development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.